LEXEO THERAPEUTICS INC
LXEONASDAQ🏆 #2438 by market capUS Equity
$145.47▲ $1.47 (+1.01%)
Simulated price1h—
24h▲ 1.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$375M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
535.2x
Expensive
Otter Score
58
Weak
No chart data available for LXEO.
Trading Snapshot
- Day Range
- $144.71 – $146.47
- 52-Week Range
- $3.99 – $10.99
- Volume
- $5.83B
- Avg Volume
- $4.21B
- Shares Outstanding
- 78.5M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $701,342
- Last Q Revenue
- $171,110
- P/E Ratio
- —
- P/S Ratio
- 535.2x
- EPS (TTM)
- $-1.45
- Dividend Yield
- —
Why Investors Own LXEO
- ✓High-growth profile — revenue up +49.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$701,342▲ +44.6% YoY
Gross Margin (TTM)
62.0%▲ +1.2% YoY
Operating Income (TTM)
$233,547▲ +44.6% YoY
Free Cash Flow (TTM)
$53,302▲ +44.6% YoY
About LEXEO THERAPEUTICS INC
A company profile for LEXEO THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
58/100
Analyst Price Target
ⓘAverage Target
$188.06
▲ +29.3% Upside
High Target$210.66
Low Target$156.03
Based on 36 analysts
Latest News & Updates
🚀
Reuters·2h ago
LEXEO THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift LXEO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
LEXEO THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.